ROBERT I TEPPER
CIK 1192595 · President, R&D · last filed 2023-02-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$92.88M
Companies
16
Total Filings
46
Lifetime Open-Market Net
-$538.42M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VYGR | 10%+ Owner | 4,813,933 | $3.30 | $15.89M | -$16.15M | 2 | 2023-02-01 |
| RVMD | 10%+ Owner | 129,258 | $216.00 | $27.92M | -$34.01M | 2 | 2022-06-10 |
| Jounce Therapeutics, Inc. (JNCE) Delisted | Director | 3,102,372 | $1.88 | $5.83M | -$630.5K | 6 | 2020-11-23 |
| Neon Therapeutics, Inc. (NTGN) Delisted | Director | 0 | — | — | $0 | 3 | 2020-05-06 |
| FULC | 10%+ Owner | 5,962,202 | $3.87 | $23.07M | $6.50M | 1 | 2019-07-22 |
| CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted | Director | 3,034,083 | $33.99 | $103.13M | $4.00M | 3 | 2019-06-10 |
| Allena Pharmaceuticals, Inc. (ALNA) Delisted | Director | 2,790,964 | $0.07 | $209.3K | $3.01M | 3 | 2019-06-07 |
| MyoKardia, Inc. (MYOK) Delisted | 10%+ Owner | 146,075 | — | — | -$129.30M | 4 | 2018-02-13 |
| CTMX | 10%+ Owner | 4,349,864 | $3.39 | $14.75M | -$1.20M | 3 | 2017-10-04 |
| KALA | Director | 649 | $0.90 | $583 | $0 | 2 | 2017-07-26 |
| Global Blood Therapeutics, Inc. (GBT) Delisted | 10%+ Owner | 4,704,964 | $68.49 | $322.24M | -$1.04M | 2 | 2017-04-10 |
| Blueprint Medicines Corp (BPMC) Delisted | 10%+ Owner | 3,453,753 | $129.46 | $447.12M | -$211.65M | 2 | 2017-02-28 |
| Sage Therapeutics, Inc. (SAGE) Delisted | 10%+ Owner | 138,917 | $8.68 | $1.21M | -$132.81M | 3 | 2016-08-19 |
| EDIT | 10%+ Owner | 3,906,176 | $2.88 | $11.25M | $0 | 2 | 2016-08-16 |
| bluebird bio, Inc. (BLUE) Delisted | Director | 4,451 | $4.97 | $22.1K | -$24.88M | 7 | 2015-02-04 |
| MILLENNIUM PHARMACEUTICALS INC (MLNM) Delisted | President, R&D | 111,587 | — | — | -$255.6K | 1 | 2007-02-13 |
Recent Filings · Page 3 of 5
46 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-11-06 | Allena Pharmaceuticals, Inc. (ALNA) Delisted | Mixed | +2,790,964 | $3.01M | EDGAR |
| 2017-10-04 | CTMX | Sell (S) | −24,777 | -$603.1K | EDGAR |
| 2017-09-27 | MyoKardia, Inc. (MYOK) Delisted | Sell (S) | −3,007,000 | -$129.30M | EDGAR |
| 2017-09-21 | CTMX | Sell (S) | −20,000 | -$360.0K | EDGAR |
| 2017-07-26 | KALA | Conv (C) | +1,621,092 | $0 | EDGAR |
| 2017-07-21 | KALA | Grant (A) | — | $0 | EDGAR |
| 2017-06-30 | CTMX | Sell (S) | −15,000 | -$240.0K | EDGAR |
| 2017-04-10 | Global Blood Therapeutics, Inc. (GBT) Delisted | Sell (S) | −31,225 | -$1.04M | EDGAR |
| 2017-04-03 | MyoKardia, Inc. (MYOK) Delisted | Other (J) | −4,250,000 | $0 | EDGAR |
| 2017-02-28 | Blueprint Medicines Corp (BPMC) Delisted | Other (J) | −6,000,000 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.